Caladrius Biosciences Inc (NASDAQ:CLBS) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 308,200 shares, a drop of 27.5% from the September 15th total of 425,100 shares. Based on an average daily volume of 761,900 shares, the short-interest ratio is presently 0.4 days.
Shares of CLBS traded down $0.05 during mid-day trading on Friday, hitting $1.70. The company had a trading volume of 91,227 shares, compared to its average volume of 409,646. The business’s 50-day simple moving average is $1.82 and its 200-day simple moving average is $2.01. Caladrius Biosciences has a 1-year low of $1.05 and a 1-year high of $3.64. The stock has a market cap of $32.85 million, a PE ratio of -2.07 and a beta of 1.49.
Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Thursday, August 13th. The biotechnology company reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.86. Research analysts forecast that Caladrius Biosciences will post -1.6 earnings per share for the current year.
In other news, Director Michael H. Davidson purchased 55,525 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were bought at an average cost of $1.80 per share, with a total value of $99,945.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.30% of the stock is owned by company insiders.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Further Reading: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.